Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification

Establishment and characterization of histologically and molecularly stable soft tissue sarcoma xenograft models for biological studies and preclinical drug testing

(2019) Jasmien Cornillie et al.   MOLECULAR CANCER THERAPEUTICS

Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer

(2018) Dorothea Rudolph et al.   CANCER RESEARCH

Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic

(2018) Joerg Rinnenthal et al.   CANCER RESEARCH

Abstract 4868: BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules

(2018) Dorothea Rudolph et al.   CANCER RESEARCH

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

(2017) Maja de Jonge et al.   EUROPEAN JOURNAL OF CANCER

Mutant p53 as a target for cancer treatment

(2017) Michael J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models

(2017) Jasmien Cornillie et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

(2016) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

(2016) Joonil Jung et al.   Nature Communications

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis

(2016) Emna Mahfoudhi et al.   Oncotarget

Clinical Overview of MDM2/X-Targeted Therapies

(2016) Andrew Burgess et al.   Frontiers in Oncology

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma

(2015) K. L. J. Bill et al.   CLINICAL CANCER RESEARCH

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

(2015) M. Andreeff et al.   CLINICAL CANCER RESEARCH

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

(2014) Ian Judson et al.   LANCET ONCOLOGY

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models

(2014) Haifu Li et al.   Translational Oncology

Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease

(2014) Patrick Schöffski et al.   Oncology Research and Treatment

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis

(2013) Camelia Iancu-Rubin et al.   EXPERIMENTAL HEMATOLOGY

Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβ

(2013) Tapasi Rana et al.   PLoS One

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

(2012) R. J. Jones et al.   MOLECULAR CANCER THERAPEUTICS

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival

(2011) A. Italiano et al.   ANNALS OF ONCOLOGY

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

(2011) M H Aziz et al.   ONCOGENE

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

(2011) M Michaelis et al.   Cell Death & Disease